Ensifentrine (RLP554) is a novel dual inhibitor of PDE3 and PDE4 that was recently (June 2024) approved by the FDA as a maintenance treatment for patients with COPD [18,39,40]. Here, PDE4A is linked to chronic obstructive pulmonary disease.